Pharmacoeconomic analysis shows that erlotinib is cost-saving versus docetaxel, and cost-effective versus best supportive care (BSC) in NSCLC.
| Autor: | Pompen, Marjolein, Novak, Annoesjka, Gok, Murat, Gyldmark, Marlene, Postmus, Pieter, Afram, Charles |
|---|---|
| Zdroj: | Journal of Thoracic Oncology; 2007 Supplement 4, Vol. 2, pS433-S433, 1p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|